Barriers to disseminating brief CBT for voices from a lived experience and clinician perspective

PloS One
Cassie M HazellMark Hayward

Abstract

Access to psychological therapies continues to be poor for people experiencing psychosis. To address this problem, researchers are developing brief interventions that address the specific symptoms associated with psychosis, i.e., hearing voices. As part of the development work for a brief Cognitive Behaviour Therapy (CBT) intervention for voices we collected qualitative data from people who hear voices (study 1) and clinicians (study 2) on the potential barriers and facilitators to implementation and engagement. Thematic analysis of the responses from both groups revealed a number of anticipated barriers to implementation and engagement. Both groups believed the presenting problem (voices and psychosis symptoms) may impede engagement. Furthermore clinicians identified a lack of resources to be a barrier to implementation. The only facilitator to engagement was reported by people who hear voices who believed a compassionate, experienced and trustworthy therapist would promote engagement. The results are discussed in relation to how these barriers could be addressed in the context of a brief intervention using CBT techniques.

References

Mar 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·I al-Issa
Feb 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·P Chadwick, M Birchwood
May 1, 1997·Psychological Medicine·A P Morrison, G Haddock
May 30, 1998·British Dental Journal·F Dean
May 2, 2000·The Journal of Nervous and Mental Disease·M B HamnerG W Arana
Jul 7, 2000·Journal of Consulting and Clinical Psychology·D J MartinM K Davis
Apr 1, 1957·Journal of Consulting Psychology·C R ROGERS
Jul 22, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Barbara J BurnsJohn Landsverk
Jan 22, 2005·The Australian and New Zealand Journal of Psychiatry·UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophren
Sep 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Wolfgang GaebelJohn S McIntyre
Jul 5, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Anthony HodsmanUNKNOWN Writing Group on the Systematic Review of Parathyroid Hormone for the Treatment of Osteoporosis
Jul 22, 2006·BMJ : British Medical Journal·Daryl Freeman, David Price
Oct 21, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gail Myhr, Krista Payne
May 23, 2009·Implementation Science : IS·Carl R MayVictor M Montori
Sep 5, 2009·Behavioural and Cognitive Psychotherapy·Catherine Evans-JonesChris Barker
Apr 12, 2011·Psychotherapy Research : Journal of the Society for Psychotherapy Research·Paul ChadwickLyn Ellett
Sep 4, 2012·Journal of Behavior Therapy and Experimental Psychiatry·H WallerT Craig
May 21, 2013·The Medical Journal of Australia·Robert M Parker
Jan 18, 2014·Journal of Mental Health·Gillian HaddockChristine Barrowclough
Feb 14, 2014·BMJ : British Medical Journal·Elizabeth KuipersTim Kendall
Aug 6, 2015·BMC Health Services Research·Frances DarkEllie Newman
Apr 7, 2016·Clinical Psychology Review·Cassie M HazellClara Strauss

❮ Previous
Next ❯

Citations

Oct 24, 2019·Journal of Mental Health·Joanne C HoldingLynsey Gregg
Aug 18, 2021·Internet Interventions : the Application of Information Technology in Mental and Behavioural Health·Chelsea ArnoldNeil Thomas

❮ Previous
Next ❯

Software Mentioned

QSR
NVivo

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.